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Summary 
Administration of cyclosporine (CS) as an immunosuppressive agent 
in clinical tr a:s plan tation is associated with multiple side 
effects including nephrotoxicity ald hypertension. These two 
effect~ could be related in that the renal changes may be 
secondary to alterations in organ blood flow. The present studies 
investigate the ability of CS to augment contractile 
responsiveness in blood vessels from normotensive rats. Isometric 
force generation was measured in isolated tail arteries and portal 
x --6 veins. ~ (8.3 I0 M) potent~a ted tail acre cy contractile 
ces ponses to sympathetic nerve s tin alatiou, exogenous 
,:or ep [nephr ine, and incr ea~e~ [,l extr acellular potassium 
concentration. Portal veins undergo spontaneous co,ltra c tions 
which are related to the firing of calcium-driven action 
potentials in the smooth muscle cells. CS significantly increased 
the frequency of these spontaneous contractile events. These 
results ~uggest that components of CS to~[city may involve a 
direct action on vascular s~,~ th mls cle and/or on vascular 
adrenergic neurot~ns,ni~slon. 
Cyc los po,-ile (CS), an or ally-act ire endecape pt [ de with potent 
immunosuppressive properties, has significantly improved survival in organ 
and bone marrow transplant recipients. Despite this success, the value of 
the drug has been lessened by its clinically significant side effects. 
Prominent among these effects, which have been extensively stLldied in both 
humans and in experimental animals, are nephrotox[c~ty aid hypertension 
(1-5). Other serious problems include: hepatic dysfunction, tremor, 
convulsions, hirsutism and gingival hyperplasia (see I, 6-8 for review). 
Changes in renal function appear rapidly following C$ administration and 
persist during chronic treatment. Acute intravenous administration of CS 
(20mg/kg) to rats caused a 26% reduction in glomerular filtration rate and a 
transient increase in blood pressure (9) as well as a 48% decrease in renal 
blood flow and an 80% increase in renal vascular resistance (8). An 
intravenous dose of 10mg/kg caused a 69% iacrease in efferent renal nerve 
activity (I0), suggesting that at least part of the effect of CS on renal 
function m~y be indirect. Chronic CS treatment is associated with elevations 
of serum urea and creatinine, depressed inulin clearance (1,2,5-8,11), and a 
red, lction in renal blood flow (12). Alth~igh ~tr,Lctural changes have been 
repo~ted [,~ the proximal tub,le of the rat (I]) and human (13), CS 
nephrotoxicity appears to be readily ceversible upon withdrawal of the drng. 
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These observations have lead several authors to speculate that the 
nephrotoxic effect of CS is mediated primarily through a hemodynamic actiou 
of the drug (6,8,14). 
The et~ology of the elevation of arterial blood p re~;1~:e is unknown and 
this change appears to develop independently of known cardiovascular risk 
factors (3). It has been postulated that generalized vascular damage is at 
least partially responsible. Pathologic changes have been observed in both 
arteriolar s,~oth muscle (5) and endothelia~ cel1~; (LS). Other authors have 
suggested that the renin-~Igiotensin-aldosterone system is involved. This 
specnlat~o,~ is based on the observation of elevations in plasma renin 
activity (PRA) in CS-treated rats (5,7) as well as augmentation by CS of 
renin release from isolated renal cortical slices (16). However, consistent 
elevations in PRA have not been observed in man (3,4,17), m~d PRA may 
actually be significantly depressed (18). Finally, Thompson and coworkers 
(3) have reported that following cardiac transplantation CS administration is 
associated with a failure of total peripheral resistance to fall 
appropriately ~en cardiac output is increased npon replacement of the 
failing heart. These patie~its develop hypertension in assoc~at~o,~ with this 
elevated vascular resistance. 
The observation of concurrent alterations in renal function, renal blond 
flow and systemic vascular resistance led us to hypothesize that cyclosporine 
alters vascular function, either directly or through an effecl o~i adrenergic 
neurotransmission. This hypothesis was tested by measuring the effect of CS 
on force develo~nent in isolated segments of vascular s,~o th muscle 
responding to physiologic stimuli. 
Methods 
Adult male Sprague-Dawley rats (300-350g) were anesthetized with sodium 
pentobarbital (50mg/kg) and tail arteries and portal veins were removed. The 
vessels were cleaned of adherent fat and connective tissue under a dissecting 
microscope. Tail arteries were cut helically i,~to strips (0.7 x 10mm), portal 
veins were slit longitudinally. The tissues were mounted vertically in an 
organ chamber containing physiologic salt solution (PSS) for measurement of 
isometric force generation as described elsewhere (19). 
Transmural nerve stimulatiou (TNS) was delivered via parallel platinn1~ 
wire electrodes. A stimulator (Grass ~del $4) delivered 9 volt square wave 
pulses of i mseC duration ove~- a range of frequencies. Ascocbic acid 
(10-4M) was added to the buffer during stlmulation periods in order to 
prevent cellular da~ge due to free radical formation at the electrodes. 
Cyclospori~e was delivered from the IV preparation (Sandimmun) and control 
experiments were performed u~i,~g the vehicle compound, cre~)phor EL plus 
~ t hanol (provided by Sandoz Pharu~ ce tt~ cals ). Other drugs L1sed were 
norepinephrine bitartrate (Lev~phed, Sterling Drug Inc., New Yo~-k, H~') v~id 
phentolamine mesylate (Regitine, CIBA Pharmaceutical Co., Summit, NJ). 
Statistical analysis was performed using either a Student's t-test with 
the Bonferroni correction or a one-way analysis of variance with a least 
significant difference test. A p-value of less than 0.05 was considered to 
be statistically significant. 
Results 
Prolouged incubation (2 hours) of unstimulated tail artery strips in CS 
(8.3 x 10-6M) did not elicit a contractile response. However, the presence 
of CS did alter the response to known vasoconstrictor stimuli whereas the 
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FIG. 1 
Responses of tail artery strips to electr;aal stimulation (I msec, 9V, 
0.1-16Hz) under control co~Idit;oqs (solid line) and in the same strips 
following a i0 rain incubation in CS (8.3 x 10-6M, broken line). Time 
control repetitions of the frequency response were not significantly 
different from control. Mean maximal response to norepinephrine was 1730 + 
155 rag. Asterisks indicate a significant d~ ~erence at p 0.05 (N=8). 
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FIG. 2 
Contractile r es pon~es (3 rain) of tail artery strips to 5.9 × IO-9M 
norepinephriae before, during and after exposure to 8.3 ~ I0-~4 CS. Bars 
represent results obtained from eight animals. The tracing depicts a typical 
experiment. Asterisk indicates a significant difference at p 0.05, (N=8). 
2574 Cyclosporine and Vascular Reactivity Vol. 40, No. 26, 1987 
vehicle soluti~a had no such properties. Figure I ~ho~ the response of the 
isolated tail artecy to adr'energ~c nerve stimulation as the frequency of TNS 
is varied fco,i 9.I to 16Hz. These neural respo:tse~ c4,i be blocked completely 
by tetrodotoxin or by phentolamine. Following a I0 rain incubatio, i in CS, a 
significa:It increase is observed in the responsiveness to TNS. Appropriate 
time control studies were aim) performed and no significant changeq ~ere 
observed i,~ the frequency response curve. 
Since CS augmented responses to e,~dogenously released norepinephrirle~ 
the effect of CS on responses to exogenously applied norepinephrine (fig, lre 
2) was evaluated. Tail arteries were n~ade to contract repeatedly (3 mi~i 
contractions) in response to a low concentration of norepinephrine (5.9 x 
10-9M, an approx. ED I0 do s e ) un ti 1 a ~a tab le co n tr ol r es po ns e was 
established. Following a I0 min incubatio1~ in CS a significant potentiation 
of the contractile response to an identical concentration of norepiJiephr[ne 
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FIG. 3 
Res pons es o f ph en to lamine -tr ea ted ( 10-6M ) tail ar ter ies to po tas s ~um 
chloride-i~iduced depolarization before (solid l i,le) and followi~g a I0 rain 
exp,)~ctre t~ CS (8.3 x I0-6~I, broken line). A~ b~" [~'c ~ L ldlcate 1 
slgnific~,~:; d~ ffe~ ~q~.e at p 0.05, (N=6). 
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An atte~pt wa~ ,~.,1~ t~ l~tl ~g~ish the site o f  action o~ ~:yc],~p,~c[~e [~ 
pote:~tiatb~g cesponse to exogenous no~epin,~ph;'[te. I~ order to discern 
between effects o;~ calcium influx and intracellular calcium handling, tail 
arterie~ were stimulated with norepinephrine (5.9 x 10 -8 , 5.9 x 10 -7 ) in 
the presence of calcium-free P, SS containing 1.0 mM ethelene glycol his 
(B-aminoethyl ether) N,N,N ,N -tetraacetlc acid (EGTA). Under these 
,:ond; tions nore pine phr ine evokes a transient c~tractile spike. The 
~gu~itude of this spike is not i~c~ea~ed by cyclosporine (8.3 x 10 -6 M, 
tab le I). 
TABLE I 
Concentration of 
Nor epi ne phr ine C on tr ol Cyclos ~or ine 
5.9 x 10 -8 M 18 + 12 mg 17 + 9 mg 
5.9 x 10 -7 M 203 "$ 57 mg 11q ~" 44 
Norepileph,-ble--h~duced phasic contractions in calcium-free PSS containing 1.0 
mM VGTA. T~ue~ were incubated [~ cycl~poi'i,~e (8.3 x 10 -6 M) for I0 
.ninutes, iN=4). 
F~gu~e 3 ill~mt~ates contractile respo,~e~ of tail artery strips which 
were induced by changing the potassium concentration of the PgS (10-50raM). 
The presence of CS (8.3 x i0- 6M) augmented the contractile response 
observed at a given concentration of potassium. These experiments were 
performed in the presence of phentolamine in order to prevent an effect of 
norepinephrine released ~=,'om depolarized adrenergic nerve endings (20). 
The portal we[~ of the rat undergoes spontaneo~l~ phasic contractile 
events under isolated c~ di tions. Figure 4 demonstrates that increasing 
con ce~1 tra t ions of ~ (8.3 x 10 -7 - 8.3 x i0- 5M, 10rain inc~Iba tions) 
increased the frequency of these myogenic events. 
,~ L~ c,,ss i o n  
These studies s,lpport olr 9reliminary observations (21) and ~uggest that 
CS can exert direct effects upon vascular s u~ootl~ ~scle. This action leads 
to an au green tat io,~ ~ co,~ tractile responsiveness ~1[ch ,nay c~l tr ibu te 
directly to c q-induced hypertension or may help to [~itiate the changes in 
renal blood flow and subsequent ne phro to xi city associated with CS 
administration (6,8,13). 
The ability of CS to potentiate responses to stimulation of the vascular 
adrenergic nerve endings could be explained by either an action of CS to 
augment adrenergic neurotransmission or a direct effect of CS on smooth 
muscle cells. Our experiments which demonstrate a CS-induced increase in 
responses to exogenous nor epinephrine support the latter conclusion. 
However, CS is known to aLlgment renal ~ympathetic nerve activity (i0) and to 
increase heart rate (5), therefore .t c~,nb[nat~ol of effects on both necves 
and smooth muscle re,~ins an attractive hypothesis. 
The effecI: ~f C~q o,~ responses of the tail artery to depolarizing 
concentrations of potassium suggests that CS ,~ay alter resting membrane 
potential, bringing the tissue closer to threshold for contraction. This 
conclusion is supported by the ability of CS to increase the frequency of 
spontaneous contractions i n  the portal vein. These spontaneou~ events have 
been sho~n to be associated with firing of a calcium-driven action potential 
in the smooth muscle cells. The frequency of their firing is increased 
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FIG. 4 
Spon ta~eou~ contractile responses in the rat p)~-tal vein under control 
conditions ~d during exposure to varying coqce, ltrations of CS (8.3 x 10 -7 
8.3 x 10-5M). Result~ are e~pressed as the number of co,ltractim~s 
occurring within a 5 rain period. Upper panel shows the response of one 
vein. Asterisks indicate a significant effect at p 0.05, (N=4). 
following depolar [za t~ on (22). However, unlike po tass i,nn-in du ced 
depolarizat;o~, cyclosporine did not increase the a~J~p]it,lde of portal vein 
contractions. T1,e reason for this difference is tlnele~r. ~ ;YDiILty of 
cyclosporine to ca~lqe partial depolarization would a1~;o be co,~sistent with 
the observed alteration in response to en do ge,~ous m~d exogenous 
norepinephrine. A decrease in membrane potential has been ~howa to [~icrease 
both release of no~'ep[nephrine from adrenergic nerve endi~igs (20) and smooth 
muscle responses to applied norepinephrine (23). 
Whatever the action nE cye]o~porine, it appears to be act[qg ;~t the 
level of t h e  ola~ma membrane. Responses of the blood vessel in calcium-free 
solution depend upon the release of intracellular calcium stores (24). In 
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our e~perLue~:ts, cyclosp~,-i~e had no effect on the magnitud,~ of the~e ~:asic 
contractions. 
AI t::o,~g'~ tJ: L-~ ele-t rophysiological e×pl anat: o,: ,~ Cg's action on 
vascular smooth n~'le ~ee,~:s reasonable, CS has pre~[o,~ly hee~ de~:onstrated 
to po~ea~ a ~:=~n'~e~ of ?the~ cellular actio~ -~:~ch co,~Id pote,~t[ally alter 
vascular function. C5 iah[B:ts phospholipase A 2 activity i,~ %~th rat ~td 
human ~ite blood cell~ (25,26) and can alter prostanoid release from human 
peripheral blood mononuclear cells (27). CS had no effect on cytosolic free 
calcium concentration in unsti,uulated rat hepatocytes or on resting calcium 
uptake into mouse lymphocytes. However, the drug was able to aug, nent the 
receptor-mediated rise [n intracellular calcium ~nen the hepatocytes ~ece 
stimulated with vasopre:~si:~ a a d  to L~crease the uptake of calcium ;nto 
,a: to gen-s timula ted I ~nphocyte~ (28,29). T]: ese observations pa_~allel o,~,- 
,'eq~Its ~ere despite an appacent lack of vasoconstrictor properties, C3 is 
able to increase vascular react[,r~ty to known constrictor stimuli. 
The clinical significance of these expeci;aeats is unclear. The present 
:na~ ,iv using I0 mln exposures to cyclospori:~e at a ~t~idies were performed pr" -:' " " 
co.:ce!~tratioa of 8.3 x I0 '~ (10 5 g/ml). Clinical ~esults (30,31) have 
suggested that optiu:l t¢ough plasma levels of cyclospo~lne i~ ~a,~ are 
somewhat lowe~ tha~ this, in the range of 2 x 10 -7 g/ml (lO-6g/ml of 
whole blood). However, the rat has been shown to be relatively resistant to 
the immunosuppre~sive effects of cyclosporine c~npared to man (II). In 
addition, while these in vitro studies involve very short exposures to this 
co~pou~:d, c]inical treatment with cyclospor[ne may continue for months o¢ 
years. Regardless, these expeci, aeats demonstrate a direct vasc~lac effect 
~ich may be associated with the hypertensive a~d ~ephrotoxic side effects of 
cyc los por ine. 
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